ReviewDrug design, development and therapy2019
Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence.
Review in Drug design, development and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 60 citations in OpenAlex.
- Epidemiology of Infections Caused by Gram-Positive Cocci-Microorganisms · 2026Review
- Antibiotic development and a path to access in India.Nature communications · 2026Article
- Efficacy and Safety of Empirically Used Levonadifloxacin (Intravenous and Oral) in the Treatment of Patients with Bone and Joint Infection: A Multicentric, Investigator-Initiated Study.Journal of orthopaedic case reports · 2026Article
- Article
- Navigating fluoroquinolone resistance in Gram-negative bacteria: a comprehensive evaluation.JAC-antimicrobial resistance · 2024Review
- Susceptibility of clinical isolates of novel pathogenJAC-antimicrobial resistance · 2024Article
- Article
- Treatment of MRSA Infection: Where are We?Current medicinal chemistry · 2024Review
- War and peace: exploring microbial defence systems as a source of new antimicrobial therapies.Frontiers in pharmacology · 2024Review
- Neonatal methicillin-resistantWorld journal of clinical cases · 2023Article
- Staph wars: the antibiotic pipeline strikes back.Microbiology (Reading, England) · 2023Review
- Antibiotics in the clinical pipeline as of December 2022.The Journal of antibiotics · 2023Review
- Potential new fluoroquinolone treatments for suspected bacterial keratitis.BMJ open ophthalmology · 2022Review
- Article
- Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin.Critical care research and practice · 2022Review
- Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update.Clinical pharmacokinetics · 2022Review
- Article
- Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones-Shaping the Fifth Generation.Pharmaceutics · 2021Review
- Pharmaceutical Approaches on Antimicrobial Resistance: Prospects and Challenges.Antibiotics (Basel, Switzerland) · 2021Review
- Structural basis of quinolone derivatives, inhibition of type I and II topoisomerases and inquiry into the relevance of bioactivity in odd or even branches with molecular docking study.Journal of molecular structure · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Levonadifloxacin and its prodrug alalevonadifloxacin are novel broad-spectrum anti-MRSA agents belonging to the benzoquinolizine subclass of quinolone, formulated for intravenous and oral administration, respectively. Various in vitro and in vivo studies have established their antimicrobial spectrum against clinically significant Gram-positive, Gram-negative, atypical, and anaerobic pathogens. The potent activity of levonadifloxacin against MRSA, quinolone-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.